Cargando…

Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy

BACKGROUND: Concomitant tumor necrosis factor (TNF) neutralization in combination with immune checkpoint inhibitors (ICIs) reduces clinical immune-related adverse events (irAEs) and appears to improve antitumor efficacy in preclinical tumor models. Agonistic antibodies targeting costimulatory recept...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacoberger-Foissac, Celia, Blake, Stephen J, Liu, Jing, McDonald, Elizabeth, Triscott, Hannah, Nakamura, Kyohei, Smyth, Mark J, Teng, Michele WL
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670957/ https://www.ncbi.nlm.nih.gov/pubmed/33199513 http://dx.doi.org/10.1136/jitc-2020-001687

Ejemplares similares

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
por: Torres, Nicolas, et al.
Publicado: (2020)

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
por: Chen, Heyu, et al.
Publicado: (2020)

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release
por: Lee, Eunhee, et al.
Publicado: (2023)

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody
por: Katoh, Yuki, et al.
Publicado: (2022)

IL-31 induces antitumor immunity in breast carcinoma
por: Kan, Tal, et al.
Publicado: (2020)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity
por: Efimova, Iuliia, et al.
Publicado: (2020)

CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell
por: Wang, Binglin, et al.
Publicado: (2021)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
por: You, Dan, et al.
Publicado: (2021)

Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity
por: Wang, Zining, et al.
Publicado: (2021)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity
por: Kalim, Khalid W, et al.
Publicado: (2022)

BRCA1 deficiency in mature CD8(+) T lymphocytes impairs antitumor immunity
por: Wu, Bogang, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
por: Zhang, Cangang, et al.
Publicado: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer
por: Ji, Dengbo, et al.
Publicado: (2020)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
por: Zhao, Songbo, et al.
Publicado: (2021)

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022)

Lactoferrin-containing immunocomplex mediates antitumor effects by resetting tumor-associated macrophages to M1 phenotype
por: Dong, Hongliang, et al.
Publicado: (2020)

Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells
por: Bai, Xiaowu, et al.
Publicado: (2022)

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
por: Hu, Jinyang, et al.
Publicado: (2022)

Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens
por: Jang, Hyun J, et al.
Publicado: (2023)

A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
por: Sánchez-Alonso, Santiago, et al.
Publicado: (2020)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
por: Shah, Sabaria, et al.
Publicado: (2023)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells
por: Landolina, Nadine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_37knklljt8n3fuq48r76g4deoe